Evidence map›Paper›PMID 38781297›Full record

ReviewCirculation research2024

HIV and Cardiovascular Disease.

Jeremiah M Afolabi, Annet Kirabo

Abstract readReview
In one paragraph

Review in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. 10th Anniversary ofBiomedicines · 2025
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeremiah M AfolabiDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.M.A., A.K.).
Annet KiraboDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.M.A., A.K.).ORCID 0000-0001-8580-9359

Funding

Immune Mechanisms of Salt-Sensitive hypertensionR01HL144941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KIRABO, ANNET · 2021 to 2025
$3.0M
Vanderbilt University Cardiovascular Medicine Training ProgramT32HL170965 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ravi Shah, Quinn Stanton Wells · 2024 to 2026
$1.2M
Salt taste sensitivity, genetics and salt sensitivity of blood pressure in HIVR21TW012635 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KIRABO, ANNET, MASENGA, SEPISO KENIAS · 2023 to 2024
$385k
FIC NIH HHS R21 TW012635NHLBI NIH HHS R01 HL144941NHLBI NIH HHS T32 HL170965
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesHIV InfectionsHeart Disease Risk FactorsHumansEditorialsinflammationmacrophagesrisk factorsviral load

Identifiers

PMID38781297
PMCPMC11132120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.